Managers / Q3 2019 · view latest →

KNOTT DAVID M

CIK 0000808722

Reported Value

$238M

Q3 2019

Positions

157

Filings on Record

2019–present window

Filed

Nov 12, 2019

original filing

Summary

Knott David M reported $238M in U.S.-listed holdings across 157 positions for Q3 2019.

Its largest position, LGND, represents 14.3% of the portfolio.

Compared with Q2 2019, the fund opened 21 new positions and exited 13.

Portfolio Metrics

Turnover

+19.3%

vs prior filed quarter

Top-10 Concentration

+57.6%

share of reported value

Largest Position

+14.3%

Ligand Pharmaceuticals Incorporated

New / Exited

21 / 13

positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value

Portfolio Composition

By security type

Common Stock · 72.6% · $173M
MLP · 8.0% · $19M
Other · 5.8% · $14M
Ltd Part · 5.7% · $13M
PUBLIC · 5.3% · $13M
Other · 2.7% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

Issuer	Move	Share Δ	Shares now	Value Δ	Value now
APOEUR Apollo Global Management, Inc.	NEW	+322.7K	322.7K	+$12M	$12M
FSICUSD FS KKR Capital Corp.	NEW	+1.53M	1.53M	+$9M	$9M
Freddie Mac 5.3 percent	NEW	+100.0K	100.0K	+$2M	$2M
Horizon Therapeutics Public Ltd. Company	NEW	+64.4K	64.4K	+$2M	$2M
BLU Bellus Health Inc.	NEW	+242.6K	242.6K	+$2M	$2M
Fannie Mae 4.75 percent Series M	NEW	+43.0K	43.0K	+$978,000	$978,000
Fannie Mae 8.25 percent Series S	NEW	+60.0K	60.0K	+$801,000	$801,000
Freddie Mac 6.02 percent Series X	NEW	+53.8K	53.8K	+$651,000	$651,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

46 positions

Export to Excel

#	Issuer	Class	% Portfolio	Value ↓	Shares
1	LGND Ligand Pharmaceuticals Incorporated history →	Common	14.69%	$35M	351.2K
2	SRCLEUR Stericycle, Inc.history →	Common	6.72%	$16M	314.1K
3	UPLDEUR Upland Software, Inc.history →	Common	6.41%	$15M	438.0K
4	FTAIEUR Fortress Trans & Infrastructure Inv. LLC history →	Common	5.66%	$13M	888.5K
5	APOEUR Apollo Global Management, Inc.history →	Common	5.13%	$12M	322.7K
6	MPLX MPLX LP history →	Common	4.31%	$10M	366.6K
7	GOOG Alphabet Inc-Cl C history →	Common	4.05%	$10M	7.9K
8	LKQ1 LKQ Corporation history →	Common	3.96%	$9M	300.0K
9	International Gaming Technologies	Common	3.58%	$9M	600.0K
10	AYAEUR The Stars Group Inc.history →	Common	3.43%	$8M	545.8K
11	FSICUSD FS KKR Capital Corp.history →	Common	3.43%	$8M	1.40M
12	Calumet Specialty Products Partners, LP	Common	3.06%	$7M	2.00M
13	MIC2USD Macquarie Infrastructure Corporation history →	Common	2.71%	$6M	163.6K
14	PFE Pfizer Inc.history →	Common	1.99%	$5M	131.9K
15	Fannie Mae 8.25 percent Series T	Common	1.61%	$4M	294.2K
16	DAL Delta Air Lines, Inc.history →	Common	1.39%	$3M	57.5K
17	JPM JP Morgan Chase history →	Common	1.14%	$3M	23.1K
18	CHCT Community Healthcare Trust Incorporated history →	Common	1.12%	$3M	60.0K
19	CLDNEUR Eiger BioPharmaceuticals, Inc.history →	Common	1.01%	$2M	234.4K
20	AOBCEUR American Outdoor Brands Corporation	Common	0.96%	$2M	390.0K
21	BioDelivery Sciences International, Inc.	Common	0.92%	$2M	517.5K
22	Freddie Mac 5.3 percent	Common	0.90%	$2M	100.0K
23	ABBV AbbVie Inc.	Common	0.89%	$2M	28.0K
24	RDUSEUR Radius Health Inc.	Common	0.79%	$2M	73.3K
25	EPRT Essential Properties Realty Trust, Inc.	Common	0.77%	$2M	80.0K
26	Freddie Mac 8.375 percent Series Z	Common	0.77%	$2M	139.5K
27	Horizon Therapeutics Public Ltd. Company	Common	0.74%	$2M	64.4K
28	XENE Xenon Pharmaceuticals Inc.	Common	0.71%	$2M	187.3K
29	CELG Celgene Corporation	Common	0.66%	$2M	15.8K
30	BLU Bellus Health Inc.	Common	0.65%	$2M	242.6K
31	BMY Bristol-Myers Squibb Company	Common	0.64%	$2M	29.9K
32	VKTX Viking Therapeutics, Inc.	Common	0.63%	$2M	218.1K
33	MIKUSD The Michaels Companies, Inc.	Common	0.62%	$1M	150.0K
34	AB AllianceBernstein Holdings PL Unit Ltd	Common	0.60%	$1M	49.0K
35	CHRS Coherus Biosciences, Inc.	Common	0.54%	$1M	63.4K
36	AIMT Aimmune Therapeutics, Inc.	Common	0.49%	$1M	56.0K
37	Foamix Pharmaceuticals Ltd.	Common	0.47%	$1M	371.1K
38	STMLEUR Stemline Therapeutics, Inc.	Common	0.47%	$1M	107.9K
39	BAC Verizon Communications Inc.	Common	0.43%	$1M	17.0K
40	RHP Ryman Hospitality Ppty Inc.	Common	0.41%	$982,000	12.0K
41	Fannie Mae 4.75 percent Series M	Common	0.41%	$978,000	43.0K
42	Global Medical REIT, Inc. Ser A Cum Pfd.	Common	0.39%	$930,000	35.0K
43	XLRN Acceleron Pharma, Inc.	Common	0.36%	$859,000	21.7K
44	KMB Kimberly Clark Corporation	Common	0.36%	$852,000	6.0K
45	CN2 Catalyst Pharmaceuticals, Inc.	Common	0.34%	$804,000	151.4K
46	DWDPEUR Dupont DE Nemours Inc.	Common	0.33%	$788,000	11.1K

Filing History

Quarter	Reported Value	Positions	Filed	Type	Links
Q3 2021	$275M	197	Nov 12, 2021	13F-HR	changes · EDGAR ↗
Q2 2021	$281M	195	Aug 13, 2021	13F-HR	changes · EDGAR ↗
Q1 2021	$234M	166	May 13, 2021	13F-HR	changes · EDGAR ↗
Q4 2020	$221M	145	Feb 12, 2021	13F-HR	changes · EDGAR ↗
Q3 2020	$170M	135	Nov 13, 2020	13F-HR	changes · EDGAR ↗
Q2 2020	$183M	127	Aug 12, 2020	13F-HR	changes · EDGAR ↗
Q1 2020	$158M	156	May 13, 2020	13F-HR	changes · EDGAR ↗
Q4 2019	$247M	152	Feb 14, 2020	13F-HR	changes · EDGAR ↗
Q3 2019	$238M	157	Nov 12, 2019	13F-HR	changes · EDGAR ↗
Q2 2019	$237M	148	Aug 12, 2019	13F-HR	changes · EDGAR ↗
Q1 2019	$251M	143	May 13, 2019	13F-HR	changes · EDGAR ↗
Q4 2018	$213M	133	Feb 12, 2019	13F-HR	changes · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.